{"entity":{"id":"centre-leon-berard","kind":"institution","name":"Centre Léon Bérard","aka":["CLB","Centre de Lutte Contre le Cancer de Lyon"],"tldr":"Lyon's cancer centre, a world reference for sarcoma and rare cancers, led by Jean-Yves Blay, who also presides over UNICANCER.","summary":"Founded in 1923, the Centre Léon Bérard is the UNICANCER centre for the Auvergne-Rhône-Alpes region and the clinical arm of the Cancer Research Center of Lyon (CRCL, with Inserm, CNRS and Lyon 1). Under Jean-Yves Blay it coordinates the French NetSarc sarcoma network and the European Reference Network for rare adult solid cancers (EURACAN). Programmes include the ProfiLER molecular profiling study, a large early-phase unit, breast oncology under Thomas Bachelot, paediatric oncology (IHOPe) and a Lyon Integrated Cancer Research Site (LYriCAN). The International Agency for Research on Cancer sits in the same city.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.centreleonberard.fr"},{"label":"Cancer Research Center of Lyon","url":"https://www.crcl.fr"},{"label":"EURACAN","url":"https://euracan.eu"}],"tags":[],"related":[],"cancers":["sarcoma","breast-hr-positive","breast-her2-positive","melanoma"],"sections":["targeted-therapy"],"technologies":["cgp","kinase-inhibitors","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":["jean-yves-blay","thomas-bachelot","patrick-mehlen","isabelle-ray-coquard"],"bottlenecks":["b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lyon","country":"FR","lat":45.743,"lng":4.856,"institutionType":"cancer-center","website":"https://www.centreleonberard.fr","university":"Université Claude Bernard Lyon 1","programs":["Sarcoma and rare cancers (NetSarc, EURACAN)","ProfiLER precision oncology","Early-phase trials","Breast oncology","Paediatric oncology (IHOPe)"]},"route":"/institutions/centre-leon-berard/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"company":[{"id":"french-sarcoma-group","kind":"company","name":"French Sarcoma Group","route":"/companies/french-sarcoma-group/"},{"id":"unicancer","kind":"company","name":"UNICANCER","route":"/companies/unicancer/"}],"institution":[{"id":"iarc","kind":"institution","name":"International Agency for Research on Cancer (IARC / WHO)","route":"/institutions/iarc/"}],"person":[{"id":"isabelle-ray-coquard","kind":"person","name":"Isabelle Ray-Coquard","route":"/people/isabelle-ray-coquard/"},{"id":"jean-yves-blay","kind":"person","name":"Jean-Yves Blay","route":"/people/jean-yves-blay/"},{"id":"patrick-mehlen","kind":"person","name":"Patrick Mehlen","route":"/people/patrick-mehlen/"},{"id":"thomas-bachelot","kind":"person","name":"Thomas Bachelot","route":"/people/thomas-bachelot/"}],"bottleneck":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"}]}}